Department of Neurosurgery, Nippon Steel Yawata Memorial Hospital, Yahatahigashi-ku, Kitakyushu, Japan.
Neuroradiology. 2010 Sep;52(9):837-45. doi: 10.1007/s00234-009-0631-7. Epub 2009 Dec 2.
Cerebral vasospasm (CV) remains a major cause of mortality and morbidity in patients with subarachnoid hemorrhage (SAH). Here, we examined the effectiveness and safety of intra-arterial injection of colforsin daropate hydrochloride (CDH).
A consecutive series of 29 patients with angiographically confirmed CV received intra-arterial CDH (IAC) therapy. Angiographic changes in spastic vessels and the cerebral circulation time (CCT) were assessed before and after IAC treatment, together with the change in clinical status.
IAC treatment was performed in 53 procedures in 29 patients. Angiographic improvement was observed following all procedures (100%), and clinical improvement was observed following 36 of 42 procedures (86%) in symptomatic cases. CCT improved significantly. At the 3-month follow-up, 19 patients (66%) showed good recovery or moderate disability on the Glasgow Outcome Scale. Major adverse effects were headache and increased heart rate.
IAC treatment was effective and safe for the treatment of CV after SAH.
蛛网膜下腔出血（SAH）后脑血管痉挛（CV）仍然是患者死亡和病残的主要原因。在此，我们研究了盐酸考福新达罗普特（CDH）动脉内注射的有效性和安全性。
连续 29 例经血管造影证实存在 CV 的患者接受了动脉内 CDH（IAC）治疗。在 IAC 治疗前后评估痉挛血管的血管造影变化和脑循环时间（CCT），并评估临床状况的变化。
29 例患者共进行了 53 次 IAC 治疗。所有操作后均观察到血管造影改善（100%），在有症状的病例中，42 次操作中的 36 次（86%）观察到临床改善。CCT 显著改善。在 3 个月的随访中，19 名患者（66%）在格拉斯哥预后量表上表现出良好恢复或中度残疾。主要不良事件为头痛和心率增加。
IAC 治疗对 SAH 后 CV 的治疗是有效且安全的。
